Allogene Therapeutics, Inc. · NASDAQ:ALLO
Kenneth Griffin reported a 7.10% stake in Allogene Therapeutics, Inc. (Schedule 13G)
Event Sep 30, 2026 · Filed Nov 16, 2026
Kenneth Griffin reported a 7.10% stake in Allogene Therapeutics, Inc., 24,680,425 shares, as a passive investor on Sep 30, 2026. Filed Nov 16, 2026 (Schedule 13G).
- Stake
- 7.10%
- Shares
- 24,680,425
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 7 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Citadel Securities GP LLC | 4.70% | 16,352,007 |
| Citadel Securities LLC | 4.10% | 14,104,798 |
| Citadel Securities Group LP | 4.70% | 16,352,007 |
| Citadel Advisors LLC | 2.40% | 8,328,418 |
| Citadel Advisors Holdings LP | 2.40% | 8,328,418 |
| Citadel GP LLC | 2.40% | 8,328,418 |
| Kenneth Griffin | 7.10% | 24,680,425 |
Source
Download original · View original at SEC
Related
- Allogene Therapeutics, Inc.
- Kenneth Griffin
- Allogene Therapeutics, Inc. shareholders
- Schedule 13G · State Street Corp · Nov 10, 2026
- Schedule 13G/A · BlackRock, Inc. · Oct 27, 2026
- Form 4 · Parker Geoffrey M. · Oct 23, 2026
- Schedule 13D/A · Tpg Gp A, LLC · Sep 30, 2026
- Form 4 · Douglas Earl Martin · Aug 25, 2026